Advertisement

Topics

Huntingtin Huntington Disease Protein or HTT Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

13:01 EDT 14 Mar 2018 | BioPortfolio Report Blog

Huntingtin Huntington Disease Protein or HTT Pipeline Review, H1 2018


Summary


Huntingtin Huntington Disease Protein or HTT pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.


The latest report Huntingtin Pipeline Review, H1 2018, outlays comprehensive information on the Huntingtin Huntington Disease Protein or HTT targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Huntingtin Huntington Disease Protein or HTT Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD Huntington disease gene. Huntingtin up regulates the expression of brain derived neurotrophic factor BDNF at the transcription level. Huntingtin is primarily associated with vesicles and microtubules.


These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 7 and 3 respectively.


Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Alzheimer's Disease, Kennedy's Disease Spinal and Bulbar Muscular Atrophy and Spinocerebellar Ataxia SCA.


Furthermore, this report also reviews key players involved in Huntingtin Huntington Disease Protein or HTT targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Huntingtin Huntington Disease Protein or HTT

The report reviews Huntingtin Huntington Disease Protein or HTT targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Huntingtin Huntington Disease Protein or HTT targeted therapeutics and enlists all their major and minor projects

The report assesses Huntingtin Huntington Disease Protein or HTT targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Huntingtin Huntington Disease Protein or HTT targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Huntingtin Huntington Disease Protein or HTT

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Huntingtin Huntington Disease Protein or HTT development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Huntingtin Huntington Disease Protein or HTT Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Huntingtin Huntington Disease Protein or HTT Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Huntington's Disease
Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG repeat, to occur many more times than it is supposed to...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...